Drug Profile
Research programme: enteropeptidase inhibitors - ObeTherapy
Alternative Names: OBE 2008Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ObeTherapy Biotechnology
- Class Small molecules
- Mechanism of Action Endopeptidase inhibitors; Enteropeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in France (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France (PO)
- 05 Dec 2012 Preclinical trials in Type-2 diabetes mellitus in France (PO)